Clinical characteristics of AML patients with high vs low CRT plasma levels
| . | All patients (n = 113) . | CRT < 200 ng/mL (n = 68) . | CRT > 200 ng/mL (n = 45) . |
|---|---|---|---|
| Sex | 58 M/55 F | 37 M/31 F | 21 M/24 F |
| Mean age, y (range) | 59.2 (22-86) | 59.9 (28-81) | 58.2 (22-86) |
| Leukocytes (× 109/L), mean | 36.6 | 38.4 | 29.3 |
| Platelets (× 109/L), mean | 82.0 | 94.5 | 76.6 |
| LDH (U/L), mean | 873.0 | 861.0 | 891.0 |
| Peripheral blasts % | 49.0 | 49.0 | 48.0 |
| Bone marrow blasts % | 68.0 | 69.0 | 62.0 |
| De novo AML, % | 87.6 | 53.1 | 34.5 |
| Secondary AML, % | 12.4 | 7.1 | 5.3 |
| From MDS, n | 5 | 4 | 1 |
| Therapy related, n | 7 | 4 | 3 |
| Cytogenetics, n (%) | |||
| Good risk* | 9 (8.0) | 7 (10.3) | 2 (4.4) |
| Intermediate risk | 51 (45.1) | 33 (48.5) | 18 (40.0) |
| Bad risk | 53 (46.9) | 28 (41.2) | 25 (45.6) |
| FAB morphology | |||
| M0 | 11 | 5 | 6 |
| M1 | 30 | 18 | 12 |
| M2 | 24 | 17 | 7 |
| M3 | 3 | 2 | 1 |
| M4 | 16 | 12 | 4 |
| M5 | 21 | 10 | 11 |
| M6 | 1 | 1 | 0 |
| M7 | 5 | 3 | 2 |
| . | All patients (n = 113) . | CRT < 200 ng/mL (n = 68) . | CRT > 200 ng/mL (n = 45) . |
|---|---|---|---|
| Sex | 58 M/55 F | 37 M/31 F | 21 M/24 F |
| Mean age, y (range) | 59.2 (22-86) | 59.9 (28-81) | 58.2 (22-86) |
| Leukocytes (× 109/L), mean | 36.6 | 38.4 | 29.3 |
| Platelets (× 109/L), mean | 82.0 | 94.5 | 76.6 |
| LDH (U/L), mean | 873.0 | 861.0 | 891.0 |
| Peripheral blasts % | 49.0 | 49.0 | 48.0 |
| Bone marrow blasts % | 68.0 | 69.0 | 62.0 |
| De novo AML, % | 87.6 | 53.1 | 34.5 |
| Secondary AML, % | 12.4 | 7.1 | 5.3 |
| From MDS, n | 5 | 4 | 1 |
| Therapy related, n | 7 | 4 | 3 |
| Cytogenetics, n (%) | |||
| Good risk* | 9 (8.0) | 7 (10.3) | 2 (4.4) |
| Intermediate risk | 51 (45.1) | 33 (48.5) | 18 (40.0) |
| Bad risk | 53 (46.9) | 28 (41.2) | 25 (45.6) |
| FAB morphology | |||
| M0 | 11 | 5 | 6 |
| M1 | 30 | 18 | 12 |
| M2 | 24 | 17 | 7 |
| M3 | 3 | 2 | 1 |
| M4 | 16 | 12 | 4 |
| M5 | 21 | 10 | 11 |
| M6 | 1 | 1 | 0 |
| M7 | 5 | 3 | 2 |
AML indicates acute myeloid leukemia; CRT, calreticulin; F, female; FAB, French-American-British classification; LDH, lactate dehydrogenase, normal < 480 U/L; M, male; and MDS, myelodysplastic syndrome.
Good risk: t(15;17), t(8;21), or inv(16); intermediate-risk: normal karyotype; bad-risk: all others.